Co-administration of a Hepatitis B vaccine with CpG-ODN 2395 induces a stronger immune response in BALB/c mice

There is little evidence of how the adjuvanted Hepatitis B Virus (HBV) vaccine, cytosine phosphoguanine oligodeoxynucleotides (CpG ODNs), affects the immune system. The purpose of this study was to determine the most effective CpG ODN adjuvant and evaluate the effects of five CpG ODNs in BALB/c mice that had received the HBV vaccine. In all, 36 female BALB/c mice were used in this lab-based experiment. The mice were divided into 12 groups and given intramuscular vaccinations. Following vaccination, all groups were monitored for 14 and 28 days. After 28 days (p value &lt; 0.0001), the vaccinated groups supplemented with CpG 2395 showed a substantial 4.4-fold elevation in signal-to-noise ratio (S/N) value of 14.1 compared to the vaccine group only (S/N = 3.22). Using real-time quantitative polymerase chain reaction for cytokine profiling, mice inoculated with both the vaccine and CpG ODNs showed reduced TNF-α levels and elevated IL-6 expression levels, which were normalized using the housekeeping gene GADPH. But the difference in IL-6 levels between the treated groups was not statistically significant (P ≥ 0.3). All treatment groups' toxicity parameters fell within the usual range. These findings led us to the conclusion that the HBV vaccine containing CpG ODN 2395 may strengthen the body's defenses against HBV infection.<br>

目前关于佐剂型乙型肝炎病毒（Hepatitis B Virus, HBV）疫苗联合胞嘧啶-磷酸-鸟嘌呤寡聚脱氧核苷酸（cytosine phosphoguanine oligodeoxynucleotides, CpG ODNs）对免疫系统的影响相关研究证据较为匮乏。本研究旨在明确最具活性的CpG ODN佐剂，并评估5种CpG ODNs对接种HBV疫苗的BALB/c小鼠的免疫调节效果。本实验室实验共使用36只雌性BALB/c小鼠，将其分为12组并实施肌肉内疫苗接种。接种后，对所有小鼠分别于14天和28天进行监测。接种28天后（p值<0.0001），联合CpG 2395的疫苗组信噪比（signal-to-noise ratio, S/N）值达14.1，较仅接种疫苗组（S/N=3.22）显著升高4.4倍。通过实时定量聚合酶链反应（real-time quantitative polymerase chain reaction）开展细胞因子谱分析后发现，同时接种疫苗与CpG ODNs的小鼠肿瘤坏死因子-α（TNF-α）水平降低，而白细胞介素-6（IL-6）表达水平升高，该检测结果以管家基因（housekeeping gene）GADPH作为内参进行归一化处理。但各处理组间IL-6水平的差异无统计学意义（P≥0.3）。所有处理组的毒性参数均处于正常参考范围内。综上，本研究结果表明，联合CpG ODN 2395的HBV疫苗可增强机体抵御HBV感染的免疫防御能力。